Variables | Cancer No 428 patients | Cancer Yes 46 patients | p | Total study population 474 patients |
---|---|---|---|---|
Age (years) | 57 ± 13 | 63 ± 11 | 0.001 | 58 ± 12 |
Female gender (%) | 63 | 72 | 0.25 | 64 |
Body mass index (kg/height2) | 25.9 ± 4.5 | 26.6 ± 4.8 | 0.31 | 26.0 ± 4.5 |
Waist circumference (cm) | 92.4 ± 13.0 | 96.4 ± 12.4 | 0.04 | 93.1 ± 12.6 |
Obese (%) | 15 | 24 | 0.14 | 16 |
Systolic blood pressure (mmHg) | 130 ± 17 | 135 ± 18 | 0.04 | 131 ± 18 |
Diastolic blood pressure (mmHg) | 82 ± 8 | 83 ± 9 | 0.23 | 82 ± 8 |
Hypertension (%) | 44 | 65 | 0.006 | 47 |
Smoke (%) | 33 | 29 | 0.99 | 32 |
Dyslipidemia (%) | 55 | 67 | 0.10 | 57 |
Diabetes mellitus (%) | 8 | 15 | < 0.001 | 9 |
Metabolic syndrome (%) | 6 | 29 | < 0.001 | 16 |
eGFR (ml/min/m2*1.73) | 94 ± 22 | 88 ± 24 | 0.13 | 93 ± 23 |
Hemoglobin (g/dl) | 13.9 ± 1.4 | 13.6 ± 1.4 | 0.80 | 13.9 ± 1.4 |
Glycemia (mg/dl) | 94 ± 22 | 106 ± 36 | 0.02 | 95 ± 25 |
Cholesterol HDL (mg/dl) | 62 [45–80] | 69 [47–91] | 0.07 | 63 [46–83] |
Cholesterol LDL (mg/dl) | 123 [93–151] | 120 [85–138] | 0.58 | 121 [99–140] |
Triglycerides (mg/dl) | 119 [80–155] | 125 [85–162] | 0.66 | 120 [78–152] |
C-reactive protein (mg/dl) | 4.3 [2.8–7.5] | 4.9 [3.5–8.9] | 0.64 | 4.4 [2.9–7.8] |
Rheumatoid factor positive (%) ** | 54 | 49 | 0.68 | 53 |
ACPA positive (%) ** | 52 | 47 | 0.80 | 51 |
Duration of disease (years) | 12.2 ± 9.3 | 14.7 ± 9.8 | 0.67 | 12.6 ± 9.2 |
CDAI * | 9.7 ± 8.9 | 13.7 ± 10.6 | 0.009 | 10.5 ± 8.4 |
DAS 28 | 2.4 ± 1.0 | 2.9 ± 1.0 | 0.08 | 2.5 ± 0.9 |
BASDAI | 5.5 ± 3.3 | 6.0 ± 3.5 | 0.16 | 5.6 ± 3.5 |
Moderate/high disease activity (%) | 32 | 55 | 0.005 | 33 |
LV mass (g/high 2.7) | 43 ± 11 | 47 ± 10 | 0.04 | 44 ± 11 |
LVEF (%) | 65 ± 6 | 67 ± 6 | 0.10 | 66 ± 6 |
Medications | ||||
 ACEi/ARBs (%) | 27 | 44 | 0.02 | 29 |
 Beta blockers (%) | 15 | 28 | 0.04 | 16 |
 Diuretics (%) | 13 | 28 | 0.01 | 15 |
 Calcium antagonists (%) | 9 | 10 | 0.72 | 9 |
 Statins (%) | 18 | 42 | < 0.001 | 20 |
 Anti-platelets agents (n, %) | 11 | 31 | < 0.001 | 13 |
 NSAIDs (%) | 36 | 21 | 0.07 | 34 |
 Methotrexate (%) | 39 | 44 | 0.34 | 40 |
 Hydroxychloroquine (%) | 8 | 2 | 0.19 | 8 |
 Corticosteroids (%) | 36 | 31 | 0.25 | 35 |
 Biologic DMARDs at enrolment (%) | 66 | 63 | 0.66 | 66 |
 Biologic DMARDs class |  |  | 0.61 |  |
  Anti-TNFα (%) ** | 72 | 66 |  | 71 |
  Anti-interleukin 6 (%)** | 10 | 12 |  | 10 |
  CTLA 4Ig (%)** | 10 | 14 |  | 11 |
  Anti-CD 20 (%)** | 8 | 8 |  | 8 |
Biologic DMARDs refractory (%) | 28 | 29 | 0.83 | 28 |